<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00005675</url>
  </required_header>
  <id_info>
    <org_study_id>N01 AR92242</org_study_id>
    <secondary_id>NIAMS-048</secondary_id>
    <nct_id>NCT00005675</nct_id>
  </id_info>
  <brief_title>Oral Type I Collagen for Relieving Scleroderma</brief_title>
  <official_title>Multicenter Phase II Trial of Oral Type I Bovine Collagen in Scleroderma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Wayne State University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of California, Los Angeles</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>UTHSC</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Medical University of South Carolina</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Beth Israel Medical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Alabama at Birmingham</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Johns Hopkins University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Georgetown University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Baltimore VA Medical Center</agency>
      <agency_class>U.S. Fed</agency_class>
    </collaborator>
    <collaborator>
      <agency>Northwestern University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Diffuse systemic sclerosis (SSc), or scleroderma, is a connective tissue disease causing
      damage to skin and other organs. The purpose of this study is to determine if taking oral
      bovine type I collagen (CI) will improve the condition of SSc patients.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      SSc is a chronic connective tissue disease that is caused by excess collagen deposits that
      damage the skin and other organs. This study will determine if a daily oral dose of bovine CI
      will improve the condition of patients with SSc.

      Patients will be randomly assigned to one of two groups. The first group will receive 500 mcg
      bovine CI daily for 15 months; the second group will receive placebo. Study visits will be
      conducted at Months 4, 8, 12, and 15. Patients will undergo physical examination and blood
      tests at each visit. Patients will also be evaluated for modified Rodnan skin score (MRSS)
      and will be given health assessment questionnaires. A chest x-ray will be conducted at study
      entry and pulmonary function tests will be conducted at study entry and Month 12.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2000</start_date>
  <primary_completion_date type="Actual">May 2005</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>Yes</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Disease condition, as measured by physical exam, modified Rodnan skin score (MRSS), health assessment questionnaires, chest x-ray, and pulmonary function tests</measure>
    <time_frame>Measured at Month 12</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">168</enrollment>
  <condition>Scleroderma</condition>
  <condition>Connective Tissue Diseases</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive oral bovine type I collagen (CI) daily for 15 months</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants will receive placebo daily for 15 months.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oral bovine type I collagen</intervention_name>
    <description>500 mcg of CI daily for 15 months</description>
    <arm_group_label>1</arm_group_label>
    <other_name>CI</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>CI placebo daily for 15 months</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Clinical diagnosis of diffuse systemic scleroderma (by American College of
             Rheumatology criteria 1980) of 10 years or less

          -  Stable skin involvement by history or physical examination 6 months prior to study
             entry

          -  Stable modified Rodnan skin score (MRSS) for 1 month prior to study entry

          -  Stable MRSS of 16 or more at screening and stable MRSS between screening and baseline
             visit

          -  Agree to use acceptable forms of contraception

        Exclusion Criteria:

          -  Participation in another clinical research study involving evaluation of another
             investigational drug within 90 days prior to study entry

          -  Concurrent serious medical condition which, in the opinion of the investigator, makes
             the patient inappropriate for the study

          -  Systemic sclerosis-like illnesses associated with environmental, ingested, or injected
             agents, such as L-tryptophan, tainted rapeseed oil, vinyl chloride, or bleomycin

          -  Limited and localized (morphea) or linear SSc

          -  Tenderness or swelling of the extremities (eosinophilic fasciitis)

          -  Pregnancy

          -  Use of certain medications

          -  Allergy to beef or dairy products

          -  Nonsteroidal anti-inflammatory drugs (NSAIDs) within 1 week before baseline visit.
             Aspirin at 325 mg or less daily for stroke or heart attack prevention is allowed.

          -  Use of herbal and some alternative therapies

          -  Any organ transplant or stem cell transplant
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Arnold E. Postlethwaite, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Tennessee at Memphis</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Alabama at Birmingham</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35294</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of California Los Angeles</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90024</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Connecticut</name>
      <address>
        <city>Farmington</city>
        <state>Connecticut</state>
        <zip>06030-1310</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Georgetown University Medical Center</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20007</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Johns Hopkins University</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21224</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boston University School Of Medicine</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02188</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wayne State University</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Beth Israel Medical Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10003</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical University of South Carolina</name>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <zip>29425</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Tennessee Health Science Center</name>
      <address>
        <city>Memphis</city>
        <state>Tennessee</state>
        <zip>38163</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The University of Texas Health Science Center at Houston</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Virginia Mason Research Center</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98101</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.uthsc.edu/ctr/</url>
    <description>Division of The Connective Tissue Research Group of the University of Tennessee, Memphis</description>
  </link>
  <reference>
    <citation>Postlethwaite AE. Can we induce tolerance in rheumatoid arthritis? Curr Rheumatol Rep. 2001 Feb;3(1):64-9. Review.</citation>
    <PMID>11177772</PMID>
  </reference>
  <reference>
    <citation>Carbone LD, McKown K, Pugazhenthi M, Barrow KD, Warrington K, Somes G, Postlethwaite AE. Dosage effects of orally administered bovine type I collagen on immune function in patients with systemic sclerosis. Arthritis Rheum. 2004 Aug;50(8):2713-5.</citation>
    <PMID>15334493</PMID>
  </reference>
  <verification_date>March 2008</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 26, 2000</study_first_submitted>
  <study_first_submitted_qc>May 26, 2000</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 29, 2000</study_first_posted>
  <last_update_submitted>May 24, 2010</last_update_submitted>
  <last_update_submitted_qc>May 24, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 25, 2010</last_update_posted>
  <responsible_party>
    <name_title>Arnold E. Postlethwaite, MD</name_title>
    <organization>UTHSC</organization>
  </responsible_party>
  <keyword>Systemic Scleroderma (SSc)</keyword>
  <keyword>Bovine Type I Collagen (CI)</keyword>
  <keyword>Multicenter</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Scleroderma, Systemic</mesh_term>
    <mesh_term>Scleroderma, Diffuse</mesh_term>
    <mesh_term>Scleroderma, Localized</mesh_term>
    <mesh_term>Connective Tissue Diseases</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

